Nasal high-frequency oscillatory ventilation and CO₂ removal: A randomized controlled crossover trial

Area of Science:

• Neonatal Medicine
• Respiratory Physiology
• Pediatric Critical Care

Background:

• Preterm infants often require noninvasive respiratory support after the initial days of life.
• Persistent oxygen requirements necessitate effective ventilation strategies to manage CO2 levels.

Purpose of the Study:

• To compare the efficacy of short-term nasal high-frequency oscillatory ventilation (nHFOV) versus nasal continuous positive airway pressure (nCPAP).
• To evaluate the impact of nHFOV and nCPAP on carbon dioxide (CO2) elimination in preterm neonates.

Main Methods:

• A multicenter, non-blinded, prospective randomized crossover study involving 30 preterm infants.
• Infants received both nHFOV and nCPAP for 1-hour periods, with each treatment administered twice in a crossover design.
• The primary outcome measured was the transcutaneous partial pressure of CO2 (TcCO2) during treatment periods.

Main Results:

• nHFOV demonstrated significantly lower TcCO2 values (47.5 ± 7.6 mmHg) compared to nCPAP (49.9 ± 7.2 mmHg; P=0.0007).
• Infants initially on nCPAP showed a significant decrease in TcCO2 when switched to nHFOV (P=0.001).
• Infants initially on nHFOV showed a non-significant increase in TcCO2 when switched to nCPAP (P=0.13).

Conclusions:

• Nasal high-frequency oscillatory ventilation (nHFOV) is more effective than nasal continuous positive airway pressure (nCPAP) in enhancing CO2 elimination.
• nHFOV offers a superior noninvasive ventilation strategy for preterm infants requiring ongoing respiratory support and oxygen therapy.